HIGH-DOSE PANCREATIC ENZYMES MAY REQUIRE CLINICAL TRIALS TO RETURN TO MARKET FOLLOWING REMOVAL DUE TO SAFETY CONCERNS; CF PATIENT REGISTRY SUGGESTED
Executive Summary
High-dose pancreatic enzyme products may require prospective clinical safety information to return to the market, several members of FDA's Gastrointestinal Drugs Advisory Committee indicated at the group's Feb. 17 meeting.